Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistryGemma N Jones, Claire Rooney, Nicola Griffin, et al.
Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
NEJM Evidence|February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate CancerNoel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2025
Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate CancerHarveer Dev, Mark Linch, Krishna Narahari, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 6, 2021
1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA)Irini Manoli, Alexandra R Pass, Elizabeth A Harrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCostanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Cancers|August 7, 2021
Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase InhibitionJeffrey R Whiteaker, Tao Wang, Lei Zhao, et al.
Molecular Oncology|December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detectionAndi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Pageof 5